Concepedia

Author

Jean‐Luc Raoul

Centre Eugène MarquisORCID

Also Known As

Christophe Louvet, Isabelle Brenot-Rossi, J J Raoul, J L Raoul, J Raoul, J-L RAOUL, J-L Raoul, J-L. Raoul, J. -L. Raoul, J. I. Raoul

523

Publications

58.6K

Citations

72

H-Index

135

Concepts

All Affiliations

Centre Eugène MarquisInstitut Paoli-CalmettesInsermHôpital PontchaillouCentre Hospitalier Universitaire de Reims
JR

About

Jean‐Luc Raoul is an author at Centre Eugène Marquis specializing in medicine, radiation oncology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

48

106

7.6K

2

Health Sciences

26

44

2.9K

3

Engineering

2

2

136

4

Social Sciences

1

1

162

5

Biomedical Engineering

1

1

24

Jean‐Luc Raoul

×

189

Publications

41.4K

Citations

65

H-Index

YearCitations

Sorafenib in Advanced Hepatocellular Carcinoma

Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro,

New England Journal of Medicine

2008

12.8K

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy, Françoise Desseigne, Marc Ychou,

New England Journal of Medicine

2011

7.6K

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Thierry Conroy, Pascal Hammel, Mohamed Hebbar,

New England Journal of Medicine

2018

2.7K

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

Éric Raymond, Laëtitia Dahan, Jean‐Luc Raoul,

New England Journal of Medicine

2011

2.5K

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Andrea Wang‐Gillam, Chung‐Pin Li, G. Bodoky,

The Lancet

2015

1.2K

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial

Jordi Bruix, Jean‐Luc Raoul, Morris Sherman,

Journal of Hepatology

2012

819

Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

Philip J. Johnson, Shukui Qin, Joong‐Won Park,

Journal of Clinical Oncology

2013

765

Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

Josep M. Llovet, Thomas Decaens, Jean‐Luc Raoul,

Journal of Clinical Oncology

2013

592

Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial

S. Gourgou-Bourgade, Caroline Mollévi, Françoise Desseigne,

Journal of Clinical Oncology

2012

480

Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial

Thierry Conroy, Marie‐Pierre Galais, Jean‐Luc Raoul,

The Lancet Oncology

2014

416

Page 1